Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.15 - A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results
00:00 - 00:00 | Presenter: Matthew Lara
- Abstract
Loading...
-
+
IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape with Novel Strategies
- 13:15 - 14:15
- 9/09/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
- Moderators:David R. Gandara, Alexander Spira, Afshin Dowlati
-
+
IS05.01 - Welcome and Introductions
13:15 - 13:20 | Presenter: David R. Gandara
- Abstract
No abstract available for this presentation
-
+
IS05.02 - The Evolving Biomarker Landscape in Advanced NSCLC
13:20 - 13:35 | Presenter: David R. Gandara
- Abstract
No abstract available for this presentation
-
+
IS05.03 - KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC
13:35 - 13:50 | Presenter: Alexander Spira
- Abstract
No abstract available for this presentation
-
+
IS05.04 - Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC
13:50 - 14:05 | Presenter: Afshin Dowlati
- Abstract
No abstract available for this presentation
-
+
IS05.05 - Discussion
14:05 - 14:15
- Abstract
No abstract available for this presentation
-
+
ES20 - Caveats, Challenges, and Controversies in Immunotherapy of Lung Cancer: Phase II and Phase III Trials*
- 20:30 - 21:05
- 9/14/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Education Session
- Track: Immunotherapy (Phase II/III Trials)
*Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.- Moderators:David R. Gandara, Myung-Ju Ahn
-
+
ES20.01 - The Statistical Imperatives of Immunotherapy Research
20:30 - 20:32 | Presenter: Mary Redman
- Abstract
No abstract available for this presentation
-
+
ES20.02 - Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer
20:32 - 20:34 | Presenter: Sanjay Popat
- Abstract
Loading... -
+
ES20.03 - Open and Unanswered Questions for Treatment and Needed Studies: What We Do and Do Not Know
20:34 - 20:36 | Presenter: Nick Pavlakis
- Abstract
No abstract available for this presentation
-
+
ES20.04 - Challenges to Expand Who Gets Immunotherapy
20:36 - 20:38 | Presenter: Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
ES20.05 - Live Discussion with Speakers
20:38 - 21:05
- Abstract
No abstract available for this presentation